Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal stem cell-derived extracellular vesicles for postmenopausal osteoporosis
IRCT20131009014957N15Phase 2Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Nov 2023
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of mesenchymal stem cell-derived extracellular vesicles and alendronate in postmenopausal osteoporosis (3 arms), sponsored by Tabriz University of Medical Sciences. Primary endpoints: Enrollment rate, Retention rate and 2 more. Started Nov 2023; status: completed.
02
Drugs
mesenchymal stem cell-derived extracellular vesiclesalendronate
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on IRCT20131009014957N15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20131009014957N15.